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Abstract
 
Experimental colitis in mice is characterized by infiltration of activated T helper (Th) cells and
macrophages into the lamina propria. Particularly, these cells expressed CD44 variant exon 7
(CD44v7)-containing isoforms. Upregulation of CD44v7 isoforms was induced by CD40 liga-
tion, an inflammation-driving interaction between activated Th cells and macrophages. To de-
fine the role of CD44v7 in colitis, mice bearing a targeted deletion for exon v7 were gener-
ated. In trinitrobenzene sulfonic acid–induced colitis, wild-type mice developed severe signs of
persistent inflammation. Mice lacking CD44v7 initially showed unspecific inflammation, then
recovered completely. The pathogenic origin was shown to reside in bone marrow–derived
CD44v7
 
1
 
 cells, because adoptive transfer experiments demonstrated an absolute requirement
for CD44v7 on hematopoietic cells for maintenance of colitis. Interleukin (IL)-10–deficient
mice, which develop a chronic Th1-driven enterocolitis, were crossbred with CD44v6/v7
 
 
 
null
mice. In IL-10 
 
3 
 
CD44v6/v7 double deficient mice, intestinal inflammation developed only
weakly and at an older age. Analysis of cell death in the inflamed lesions revealed that mononu-
clear cells in the CD44v7 null infiltrates had higher rates of apoptosis than those from wild-type
mice. Thus, the region encoded by CD44v7 appears to be essential for survival of effector lym-
phocytes, resulting in persistence of inflammation.
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Introduction
 
In inflammatory bowel disease (IBD),
 
1
 
 such as Crohn’s dis-
ease and ulcerative colitis (1–3), an aberrant mucosal ho-
meostasis is observed accompanied by an upregulation of
proinflammatory cytokines (4, 5). Similar findings have
been described in mouse models of colitis, e.g., in a chemi-
cally induced colitis in which the contact sensitizer trini-
trobenzene sulfonic acid (TNBS) is locally administered, in
transgenic mice bearing targeted deletions for cytokines
and receptors important in T cell development or activa-
tion and in immunodeficient mice receiving defined T cell
subpopulations (6–8).
Pathogenic cells in inflamed lesions of autoimmune dis-
eases have an activated phenotype and are known to ex-
press high levels of CD44 that appear to be pivotal for ex-
travasation into inflamed tissues (9). Furthermore, the
transmembrane glycoprotein CD44 has been proposed to
mediate costimulatory functions (10). A large number of
isoforms generated by strictly controlled alternative splicing
(11, 12) is found in association with activated lymphocytes,
hematopoiesis, and tumor progression (13). These findings
prompted us to evaluate whether blockade of defined
CD44 variant (CD44v) isoforms might provide a specific
and effective therapeutic strategy for inflammatory diseases.
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Abbreviations used in this paper:
 
 AICD, activation-induced cell death;
BL/6, C57BL/6; ES, embryonic stem; HPRT, hypoxanthine ribosyl-
transferase; IBD, inflammatory bowel disease; LPMC, lamina propria
mononuclear cell; RT, reverse transcription; TNBS, trinitrobenzene sul-
fonic acid; TUNEL, terminal deoxynucleotidyl transferase–mediated
dUTP nick end labeling; v, variant. 
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In fact, administration of an mAb specific to CD44v7 effi-
ciently cured TNBS-induced colitis in mice (14, 15).
However, it was not clear from these studies whether the
antibody blocked CD44 receptor functions or delivered a
transmembrane stimulus. CD44v7 has recently been dem-
onstrated to be upregulated in peripheral blood leukocytes
of patients with chronic IBD (16).
We generated mice deficient for CD44 variant exons 6
and 7, known to be upregulated in leukocyte activation
and hematological malignancies in humans, rats, and mice
(13). Stimulation of CD40 ligation caused upregulation of
CD44v7 isoforms. Deficiency for CD44v6/v7 prevented
susceptible mice from developing experimental colitis. The
inflammation promoting potential resided on CD44v7
 
1
 
bone marrow cells. These cells appeared to sustain the in-
flammatory process by inhibiting apoptosis.
 
Materials and Methods
 
Vector Construction and Generation of CD44v7- and CD44v6/v7-
deficient Mice. 
 
The mouse CD44 variant region was isolated
from a 129SV genomic library. (The mouse CD44 full-length
cDNA sequence is available from EMBL/GenBank/DDBJ under
accession no. AJ251594.) Two 34-bp loxP sites were inserted in
direct repeats into a single SacI site 3
 
9
 
 of exon v6 and at the 5
 
9
 
end of the neo
 
r
 
 cassette, which was then inserted into the single
Bst1107I site 5
 
9
 
 of exon v6. The HSV-tk cassette was blunt li-
gated into the BamHI site. For electroporation, the targeting vec-
tor was linearized with PvuI and 20 
 
m
 
g was transfected into 10
 
7
 
R1 embryonic stem (ES) cells. ES cells were maintained on a
feeder layer of embryonic fibroblasts in the presence of leukemia
inhibitory factor. After selection with G418 (300 
 
m
 
g/ml) and
gancyclovir (10
 
2
 
6 
 
M), 415 clones were analyzed by Southern blot
using a 5
 
9
 
 external probe (StuI–EcoRI; see probe A in Fig. 1 C).
SacI digests revealed that two clones showed homologous recom-
bination (frequency 1/200). Positive clones were injected into
C57BL/6 (BL/6) blastocysts and chimeric male offspring were
mated with 129SV and BL/6 females. Heterozygous 129SV mice
were intercrossed to produce homozygous 129SV mice, targeted
with loxP sites flanking exon v6. Heterozygous offspring of the
BL/6 females was backcrossed for 10 generations onto the BL/6
background. As reverse transcription (RT)-PCR analyses re-
vealed that homozygous v6 loxP-targeted mice do not express
exon v7 (data not shown), further Southern blot analyses were
performed using probes 3
 
9
 
 of exon v6. Probe B (EcoRI–EcoRV)
indicated loss of 1.6 kb in the region of exon v7, which only oc-
curred in one of the two positive ES clones.
To generate v6-deficient mice, loxP-positive ES clones were
transiently transfected with pBS185, a plasmid expressing cre re-
combinase (17). Cells were grown in the absence of G418, and
clones obtained were tested for the loss of G418 resistance.
Southern blotting of SacI-digested genomic DNA indicated that
one clone (no. 126/28) showed the correct genotype. ES cells
were again injected into BL/6 blastocysts, and male chimeric off-
spring were mated with 129SV, BL/6, or BALB/c females. Het-
erozygous 129SV mice were intercrossed to produce homozy-
gous 129SV mice, deficient for exon v6. Heterozygous offspring
of the BL/6 females was backcrossed for 10 generations onto the
BL/6 background. Heterozygous BALB/c females were back-
crossed for six generations onto the BALB/c background. Mice
were kept under specific pathogen-free conditions; 10–20-wk-
 
old mice were used for inducing colitis with TNBS, all of them
on either 129SV or BALB/c background.
IL-10
 
2/2
 
 mice backcrossed to BL/6 for eight generations were
provided by M. Kopf (Basel Institute for Immunology) with per-
mission of W. Müller (Institute for Genetics, Cologne, Germany;
18) and cross-bred with CD44v6/v7
 
2/2
 
 BL/6 mice. Groups of
6–8 mice at an age of 10–13 wk (a total of 94 mice) were placed
into normal housing conditions and investigated weekly for over-
all health and weight. All mouse experiments were performed in
accordance with Swiss and institutional animal care guidelines.
 
Generation of Antibodies Specific for Mouse CD44v.
 
The CD44v6/
v7-deficient mice were also used to obtain mAbs with specificity
for v6 (LN6.1) and v7 (LN7.1 and LN7.2). Mice (CD44v6/v7
 
2/2
 
)
or rats were immunized with 100–200 
 
m
 
g of CD44v4–10/glu-
tathione 
 
S
 
-transferase (GST) fusion protein, three times over a
period of 12 d. 2 d after the last immunization, the regional LNs
were taken and cell fusion was performed using the cell line X63-
Ag8. The following mAbs were obtained: anti-CD44v10 (termed
LN10.1, rat IgG
 
1
 
), anti-CD44v7 (LN7.1, mouse IgG
 
1
 
; LN7.2,
mouse IgG
 
2a
 
; and LN7.3, mouse IgM), and anti-CD44v6
(LN6.1, mouse IgG
 
2a
 
). The epitopes recognized by the mAbs
were mapped using 16-mer peptides (overlapping by eight amino
acids) covering the region v4–v10 in ELISAs coated with
CD44v4–10/GST, yielded the following specificities: FQNG-
WQGKNPPTPSED (LN6.1), QEDVSWTDFFDPISHP (LN7.1),
and FFDPISHPMGQGHQTE (LN7.2). A CD44v10-specific
mAb had already been generated by immunizing rats. It re-
cognizes the sequence PTDTTTSVEGYTFQYPDTMENGTL
(LN10.1).
mAbs were purified from cell culture supernatant using protein
G–Sepharose columns (Amersham Pharmacia Biotech), and iso-
types of the mAbs were determined using commercially available
kits (Serotec; Roche Molecular Biochemicals). The purified anti-
bodies were dialyzed and concentrated using Centricon concen-
trators (Amicon) and labeled with biotin-
 
N
 
-hydroxy-succinimide
ester (Sigma-Aldrich). Secondary antibodies with enzymatic or
fluorescent labels were purchased from Southern biotechnology
Associates, Inc., and titrated for use at optimal concentrations. Bi-
otinylated isotype control mAbs (rat IgG
 
1
 
, mouse IgG
 
1
 
, mouse
IgG
 
2a
 
) were purchased from BD PharMingen and used at identi-
cal concentrations as the respective mAbs. Data were acquired in
a FACSCalibur™ (Becton Dickinson) and analyzed with the
CELLQuest™ program (Becton Dickinson).
 
Induction of TNBS Colitis. 
 
1 wk before induction of colitis,
mice were transferred from specific pathogen-free to conven-
tional conditions. Mice at an age of 10–16 wk were separated
into groups of six to eight mice. In the colitis group, mice were
given 200 
 
m
 
l TNBS (2.5% wt/vol; Sigma-Aldrich) in 50% etha-
nol. Control mice received identical injections of 50% ethanol in
PBS. A 2.5 F catheter was inserted into the colon up to the ap-
pendix, the hapten was applied, and the animals were kept in a
vertical position for 30 s.
 
Histological and Immunohistological Analysis. 
 
Colons were
macroscopically investigated, and small pieces were embedded in
Tissue-Tek (Sakura), frozen on dry ice, and stored at 
 
2
 
70
 
8
 
C.
Cryostat sections (6 
 
m
 
m) were air dried and stained with hema-
toxylin and eosin according to standard protocols. The histologi-
cal changes were graded semiquantitatively into no signs of in-
flammation (grade 0); low level of leukocyte infiltration (grade 1);
high level of leukocyte infiltration, thickening of the colon wall
(grade 2); and transmural infiltration of leukocytes with loss of
goblet cells, thickening of the colon wall (grade 3).
For immunohistological evaluations, sections were fixed in 
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chloroform/acetone for 2 min. Sections were incubated in PBS
containing 0.2% FCS and 2% H
 
2
 
O
 
2
 
 to quench endogenous per-
oxidase activity, followed by incubation with human serum (10%
in PBS) to block nonspecific binding of antibodies. Tissue was
washed twice with an isotonic sodium chloride buffer and then
incubated for 30 min with the biotinylated antibodies LN6.1
(anti-v6) and LN7.2 (anti-v7). Detection of immunolabeled cells
was performed with streptavidin-biotinylated horseradish peroxi-
dase (Amersham Pharmacia Biotech), and visualized by 3-amino-
9-ethylcarbazol (ICN Biomedicals). Negative controls were pro-
cessed identically, apart from omitting the primary antibody.
 
Lamina Propria Mononuclear Cell Preparation and Cultivation.
 
Mice were killed by CO
 
2
 
 at days 2, 5, and 9 after TNBS applica-
tion. The colon was trimmed of fat, mesenteric tissue, and Peyer’s
patches. The colon was opened longitudinally and cut into 3-mm
pieces. Intraepithelial lymphocytes were removed by incubation
in HBSS containing 5 mM EDTA for 30 min at room tempera-
ture under vigorous agitation. After three washing steps with
PBS, the tissue was incubated for 45 min at 37
 
8
 
C in RPMI 1640
medium, supplemented with 5% FCS and 0.2 mg/ml collagenase
D (Roche Molecular Biochemicals) and 0.1 mg/ml DNAse I
(Sigma-Aldrich). Cells were separated from tissue debris by filtra-
tion through a nylon gauze followed by purification through a
discontinuous 40/70% Percoll gradient (Amersham Pharmacia
Biotech) for 60 min at 1,500 
 
g
 
. This procedure yielded 0.5–1 
 
3
 
10
 
6
 
 cells/mouse.
 
Cell Culture. 
 
LNs from wild-type and v6/v7
 
2/2
 
 mice were
isolated and single cell suspensions were prepared. Cells were in-
cubated overnight in RPMI medium, and supplemented with
10% FCS and 20 U/ml IL-2. Activation was induced by 1 
 
m
 
g/ml
PHA (Wellcome) or coculture with CD40L secreting J558 my-
eloma cells in transwells (Costar) overnight.
 
Reconstitution of Lethally Irradiated 129SV Mice with CD44v7-
deleted Lymphocytes. 
 
129SV mice were lethally irradiated with 8
Gy followed by reconstitution with 5 
 
3
 
 10
 
6
 
 bone marrow cells
from either CD44v7
 
2/2
 
 (
 
n
 
 5 
 
10) or CD44v7
 
1/1
 
 (
 
n
 
 5 
 
5) mice
(129SV or BALB/c background) intravenously. 6 wk after recon-
stitution, mice were treated with a single application of TNBS as
described above.
 
Semiquantitative Analysis of CD44 Isoforms by RT-PCR.
 
Mononuclear cells prepared from inflamed and noninflamed co-
lon mucosa were resuspended in guanidium isothiocyanate
(GITC), and cDNA was prepared as described previously (19).
For semiquantitative analysis, cDNA amounts were equilibrated
by standardizing to the mouse hypoxanthine ribosyltransferase
(HPRT) gene product. The HPRT primers GCCCCAAAATG-
GTTAAGGTTGC and GACAACGATTTACTGAAAGTGGG
yield a product of 701 bp. Identical amounts of cDNAs were
then used to perform CD44v-specific PCR. The primers used for
CD44 amplification were CCGGAGCACCTTGGCCACC and
CCTGGTTCGCACTTGAGTGTC, which are flanking the al-
ternatively spliced variant region yielding a product of 107 bp for
CD44s when no variant exons are included (see Fig. 1 B). The
PCR regime was 10 s at 96
 
8
 
C, 15 s at 55
 
8
 
C (for HPRT) or 60
 
8
 
C
(for CD44), 1 min at 72
 
8
 
C for 30 cycles, followed by a final 10
min at 72
 
8
 
C in a Hybaid OmniGene machine.
Products were separated on 1.2% agarose gels and alkaline-
transferred onto Hybond N
 
1
 
 membranes (Amersham Pharmacia
Biotech). For specific detection, PCR products from CD44v ex-
ons were prepared, gel purified, and 
 
33
 
P-labeled using the
Megaprime DNA labeling system from Amersham Pharmacia
Biotech. After stringent hybridization and washing, blots were
exposed to BioMax films (Eastman Kodak Co.) for 6 h.
 
Results
 
CD44 Isoform Expression in Colitis and Generation of
CD44v7- and CD44v6/v7-deficient Mice.
 
Activation of
human and rat lymphocytes causes a preferential upregula-
tion of CD44v6-containing isoforms (19, 20). Immunohis-
tochemical analyses revealed that CD44v7-containing iso-
forms were also present in the weakly inflamed infiltrates in
the colonic mucosa of TNBS-treated BALB/c mice (Fig. 1
A, top left). About 50% of the cells in the infiltrates with
severe colitis were positive for CD44v6 (not shown) and
v7 (Fig. 1 A, bottom right). Lamina propria mononuclear
cells (LPMCs) from inflamed colons were mostly CD4
 
1
 
 T
cells (40–70%) and CD11b
 
1
 
 macrophages (10–30%) (data
not shown).
To analyze the composition of CD44 splice variants, we
performed RT-PCR analyses of LPMCs from inflamed
and noninflamed mucosa (Fig. 1 B). Whereas in LPMCs
from noninflamed mucosa only exons v3 and v10 were ex-
pressed (included into the standard framework either as a
single exon or, for v10, combined with exons v8 and v9)
and no exon v7, in LPMC inflamed mucosa, especially
variant isoforms containing exon v7 were detected (Fig. 1
B). RT-PCR analysis of Th1-polarized CD4
 
1
 
 splenic T
cells revealed a very similar pattern as LPMCs from in-
flamed mucosa. In contrast, the pattern of LPMCs in non-
inflamed mucosa resembled one of the naive T cells and
Th2-polarized CD4
 
1
 
 splenic T cells (19; and Johansson,
B., and U. Günthert, manuscript in preparation).
The v6 exon of the CD44 gene (Fig. 1 C) was targeted
in murine R1 ES cells with flanking loxP sites and 5
 
9
 
 inser-
tion of a neo expression cassette. Detailed Southern blot
analysis indicated that a deletion occurred in the region of
exon v7, most likely during homologous recombination in
one of the two ES clones. Thus, v6 loxP-targeted mice
were devoid of exon v7, but retained expression of the
other isoforms. The loxP-targeted ES cell clones were tran-
siently transfected with a cre recombinase–expressing plas-
mid, pBS165 (17), and a neo-sensitive clone revealed
proper excision of the loxP-targeted region, R1-126/28.
Heterozygous 129SV mice were backcrossed with BL/6
mice for 10 generations and with BALB/c mice for 6 gen-
erations. Homozygous mice were born at the expected fre-
quency on all backgrounds. Female and male mutant mice
(v7
 
2/2
 
 and v6/v7
 
2/2
 
) were fertile and did not show obvi-
ous abnormalities. The distribution of subpopulations of
hematopoietic cells in central and peripheral lymphoid or-
gans appeared unaltered (data not shown).
Activation of LN cells from BALB/c mice with PHA in
vitro led to a 12-fold increase of CD44v6 and v10 (not
shown) surface expression, but v7 expression was almost
unchanged (Fig. 1 D). Cocultivation of LN cells with
CD40L-secreting J558 cells (21) increased the CD44v7 ex-
pression sixfold, but did not affect v6 (Fig. 1 D). Similar
upregulation of v7 was achieved by treatment of LN cells
with anti-CD40 antibodies (data not shown). Neither PHA
nor CD40L induced expression of v6 and v7 in CD44v6/
v7
 
2/2
 
 mice. Notably, CD44’s expression was unaffected in 
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Figure 1.
 
(continued on facing page). 
 
Expression of CD44v7 and generation of CD44v6/v7
 
2/2
 
 mice. (A) Immunohistochemical analysis of CD44v7 iso-
forms in inflamed mucosa showing expression of slightly inflamed mucosa (top left) as well as in large transmural infiltrates (bottom right). IM7.8.1 (anti–
pan-CD44) reveals broad staining (bottom left). Original magnifications: 
 
3
 
200; negative control, 
 
3
 
100. (B) cDNA was prepared from LPMCs of nonin-
flamed and inflamed large intestines of TNBS colitis, and semiquantitative RT-PCR of CD44 variant isoforms was performed using primers I and II
located within the standard region, flanking the variant part. Amounts of cDNA were equilibrated to HPRT- and CD44-specific reactions blotted and
hybridized with exon-specific probes. Reactions for v3, v7, v10, and the standard region (CD44s) are shown in the bottom panel. Presence and size of a
signal allowed for the composition of the variant isoforms expressed, which are indicated in the scheme above. LPMCs from inflamed colons express a va-
riety of CD44v isoforms, mostly including v7, whereas LPMCs from noninflamed tissue express exons v3 and v10 as a single exon, as well as v10 in com-
bination with v8 and v9. The gray bars in the upper region of the scheme represent the CD44 standard region, which is expressed with similar intensity in
all preparations. (C) Genomic targeting of CD44 exons v6 and v7. Analysis of ES clones by Southern blotting using a 5
 
9
 
 external probe (StuI–EcoRI;
probe A). Southern blot analyses using probe B (EcoRI–EcoRV) indicated loss of 1.6 kb in the region of exon v7, which only occurred in one of the two 
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the v6/v7
 
2/2
 
 mice and similarly strong as in the wild-type
mice (Fig. 1 D).
 
CD44v7-deleted Mice Do Not Develop Colitis.
 
A small
number of either wild-type 129SV (19%, 10/52) or
CD44v7
 
2/2
 
 mice (18%, 11/61) died within 2 d after rectal
administration of TNBS in ethanol (Fig. 2 A). However, all
CD44v7
 
2/2
 
 mice that survived the acute injury were pro-
tected from colitis and were clinically normal at day 9.
Similar findings (survival rate 78%, 32/41) accounted for
CD44v6/v7
 
2/2
 
 mice. In contrast, only 44% of wild-type
mice survived, and 92% of these developed severe colitis
with wasting disease. The clinical data were consistent with
the histological findings. CD44v7
 
2/2
 
 and CD44v6/v7
 
2/2
 
mice responded to the vehicle (50% ethanol) injection with
an acute mucosal injury, ulceration, and hemorrhagic infil-
trates within the first 2 d (Fig. 2 B). They completely re-
covered thereafter with macroscopically and histologically
normal colons on day 9, when those of wild-type mice still
showed severe strictures and inflammation (Fig. 2 B). Mice
heterozygous for CD44v7 (or CD44v6/v7, not shown) did
not differ from normal wild-type mice (Fig. 2 B). Thus,
CD44v7 is essential for exacerbation of experimental
colitis.
Analysis of cytokine production of LPMCs (protein and
mRNA levels) during the 9-d course of TNBS treatment
revealed a downregulation of Th1-type cytokines and
chemokines (IL-12, IFN-
 
g
 
, and macrophage inflammatory
protein 1
 
a 
 
and 1
 
b
 
) and a corresponding upregulation of
 
Th2-type cytokines (IL-4, IL-10, and TGF-
 
b
 
) in
CD44v7
 
2/2
 
 and CD44v6/v7
 
2/2
 
 mice in contrast to wild-
type mice (or CD44v7
 
1/2
 
 and CD44v6/v7
 
1/2
 
 mice) (data
not shown).
 
Resistance to TNBS Colitis Can Be Transferred from
CD44v7-deficient Mice into Lethally Irradiated Susceptible
Mice.
 
As expression of CD44v7 and v6/v7 isoforms on
both epithelial cells and leukocytes was deleted in our tar-
geted mice, either cell type might be participating in dis-
ease progression. Therefore, lethally irradiated 129SV mice
were reconstituted with bone marrow from either
CD44v7
 
2/2
 
 or CD44v7
 
1
 
/
 
1
 
 mice (129SV). All 129SV mice
that received bone marrow from 129SV CD44v7
 
2/2
 
 mice
survived a single application of TNBS given 6 wk after
transplantation, whereas mice given bone marrow from
129SV CD44v7
 
1
 
/
 
1
 
 mice developed colitis (42% sur-
vival; Fig. 3). Similar data were obtained by transfer of
CD44v7
 
2/2
 
 and v7
 
1
 
/
 
1
 
 (BALB/c) bone marrow into
BALB/c mice (88 vs. 22% survival). Hence, development
of the inflammatory reaction requires CD44v7-proficient
hematopoietic cells.
 
Targeted Deletion of CD44v6/v7 Exons Delays Onset and
Ameliorates the Intensity of Chronic Enterocolitis in IL-10
 
2/2
 
Mice.
 
The importance of IL-10 in the regulation of mu-
cosal inflammation has been demonstrated in several animal
models (22). IL-10
 
2/2
 
 mice spontaneously develop a gen-
eralized enterocolitis under conventional housing condi-
tions, and the inflammation can be prevented by the
 
positive ES clones. The restriction sites are: St, StuI; R, EcoRI; BE, BstEII; S, SacI; BX, BstXI; Bst, Bst1107I; V, EcoRV; and B, BamHI. (D) LN cells were
prepared and stimulated overnight with PHA or cocultured with CD40L-transfected J558 cells in transwell plates (Costar). Surface staining was performed
using pan-CD44–specific mAb (clone IM7.8.1)–FITC, and biotinylated CD44v6 (LN6.1 or BMS145; Bender MedSystems) specific and v7 (LN7.1) specific
antibodies. Avidin-PE was used for detection of the CD44v expression. Percentage of double labeled cells is indicated in the upper right quadrant. 
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administration of recombinant IL-10 (18). Intestinal in-
flammation in IL-102/2 mice appears to be due to the lack
of the general suppressive effects of IL-10 on cytokine pro-
duction by macrophages and Th1 cells (23). IL-10 treat-
ment also ameliorates inflammation in TNBS-induced
colitis and in a T cell subset transfer model (24, 25). In ad-
dition, local administration of IL-10 has been beneficial for
patients with Crohn’s disease (26).
IL-10 is upregulated in TNBS-treated CD44v6/v72/2
mice and anti-v7–treated wild-type mice (14, 15; data not
shown). To investigate the role of CD44v6/v7 in the
chronic enterocolitis that spontaneously develops in IL-
102/2 mice (18), we intercrossed both strains. Groups of six
mice, each with different genotypes, were kept under
normal housing conditions. All IL-102/2 mice (either
CD44v6/v71/1 or CD44v6/v71/2) developed chronic
colitis with macroscopically obvious anal prolapses at 12–18
wk of age, and weight loss starting around 25 wk of age
(Fig. 4 A). A substantial mucosal infiltrate of mononuclear
cells was present in 12-wk-old animals, whereas at 31 wk
infiltrates were detectable in both mucosa and submucosa
with transmural ulcerations (Fig. 4 B). At this age, disease
was observed in 100% of the IL-102/2 (CD44v6/v71/1 or
1/2) mice. Control mice (IL-101/1 and any CD44v6/v7
genotype) did not spontaneously develop colitis and con-
tinually gained weight within the observation period (Fig.
4 A). The colons of these mice showed normal morphol-
ogy (Fig. 4 B). Double deficient mice (IL-102/2 CD44v6/
v72/2) developed well until an age of 24 wk, then they
slowly started to lose weight (Fig. 4 A). Histological evalu-
Figure 2. CD44v7- and CD44v6/v7-
deficient mice overcome TNBS-induced
colitis. (A) Survival of mice treated with
TNBS. Mice were kept under normal
housing conditions and at an age of 10–16
wk, were separated into groups of 6–8 mice
(a total of 61 CD44v72/2 mice and 52
129SV wild-type [wt] mice), and either
given 200 ml TNBS (2.5% wt/vol; Sigma-
Aldrich) in 50% ethanol, or 200 ml 50%
ethanol in PBS (control). (B) Histology of
CD44v7 and CD44v6/v72/2 mice treated
with TNBS. Frozen sections of colons 2
and 9 d after TNBS treatment were stained
with hematoxylin and eosin. Original mag-
nifications: 3100.2059 Wittig et al.
ation revealed only small areas of inflammation in the mu-
cosae (Fig. 4 B). These double deficient mice did not have
the shortened life span typical of IL-102/2 CD44v6/v71/1
mice. Analysis of mucosal leukocytes showed a strongly di-
minished IL-12 production in the double deficient mice in
contrast to IL-102/2 CD44v6/v71/1 mice (protein and
mRNA levels; data not shown). A total of 52 double defi-
cient mice were analyzed, and all showed strongly reduced
inflammation. Thus, CD44v6/v7 is required for the initia-
tion and maintenance of the disease that spontaneously de-
velops in IL-102/2 mice.
Increased Apoptosis of Leukocytes in Inflamed Regions of
CD44v6/v7-deficient Mice. As described previously, inter-
actions involving CD40 and CD40L result in an immediate
and strong increase of pan-CD44 expression on Th1 cells
as well as on the APCs (10). Using specific reagents, we
now observed that CD40 ligation induces an upregulation
of CD44v7 expression on mouse LPMCs, which may be
important for the interaction between Th1 cells and mac-
rophages to sustain the inflammatory reaction. Blocking of
the CD40–CD40L interaction, which is pivotal for Th1
cell priming and induction of IL-12 secretion in mono-
cytes/macrophages (27), prevents TNBS-induced colitis
(28). Deficiency for the CD44v6/v7 isoforms could thus
abrogate the Th1–macrophage interaction and prevent the
development of a transmural colonic inflammation with
massive accumulation of LPMCs.
A further important feature of CD40–CD40L interac-
tions is the enhancement of clonal T cell expansion and the
delay in their activation-induced cell death (AICD) (29–
31). Furthermore, there is strong evidence that a balance
between the production of autoreactive T cells and their
rapid elimination by AICD is perturbed in autoimmune
diseases (32). Therefore, we analyzed apoptotic activity in
early inflammatory lesions of wild-type and CD44v7-defi-
cient mice. Terminal deoxynucleotidyl transferase–medi-
ated dUTP nick end labeling (TUNEL) assays revealed
three- to fourfold higher numbers of apoptotic cells in
CD44v72/2 or CD44v6/v72/2 colons compared with those
from similarly TNBS-treated wild-type mice (Fig. 5 A).
However, in noninflammatory untreated CD44v6/v72/2
mice, such an increase in apoptotic nuclei was not observed
(Fig. 5 A). Counts of apoptotic nuclei per field were 52 (6
20) for CD44 wild-type; 23 (6 11) for CD44v6/v72/2
control; 192 (6 43) for CD44v6/v72/2; and 183 (6 49) for
Figure 3. Resistance against TNBS colitis can be transferred by bone
marrow from CD44v72/2 mice. 129SV and BALB/c mice were lethally
irradiated with 8 Gy and reconstituted with 5 3 106 bone marrow cells
(bm) from either CD44v72/2 ( n 5 10) or CD44v71/1 ( n 5 5) mice
(129SV or BALB/c background). TNBS was applied 6 wk after reconsti-
tution.
Figure 4. CD44v6/v7 deficiency can largely rescue colitis in IL-102/2
mice. (A) Mice (six per group) proficient for IL-10 (1/1 or 1/2) and
any CD44v6/v7 genotype (m), IL-10 (2/2) and CD44v6/v7 (1/1 or
1/2) mice (d), and mice deficient for both markers (r) were weighed
weekly (reference 23). (B) Histology of CD44v6/v7 3 IL-10 mice. Fro-
zen sections of colons from three different genotypes of mice taken from
the experiment in A at 31 wk of age were stained with hematoxylin and
eosin. Sections show transmural colitis in a v6/v71/2 IL-102/2 mouse; no
signs of colitis in a v6/v72/2 IL-101/2 mouse; and low levels of leukocyte
infiltration in a v6/v72/2 IL-102/2 mouse. Bar, 40 mm; original magnifi-
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CD44v72/2. Concomitantly, LPMCs from CD44v72/2
and CD44v6/v72/2 inflamed lesions revealed more apop-
totic cells compared with LPMCs from TNBS-treated
wild-type mice by assaying for annexin V binding and pro-
pidium iodide uptake (Fig. 5 B).
Discussion
Targeted deletion of exons 6 and 7 of the variant region
of CD44 in mice allowed us to demonstrate in hapten-
induced experimental colitis, by adoptive transfer as well as
by crossing the mutants with IL-102/2 mice, that expres-
sion of these CD44v regions on activated hematopoietic
cells, particularly of inflamed mucosa, is essential for pro-
moting and maintaining unbridled Th1 reactions in mouse
models for IBD. The requirement for CD44v6/v7 was
clearly pointed out due to the fact that the isoform-specific
mutant mice were not affected in the expression of the pre-
dominant hematopoietic CD44 isoform. The region en-
coded by exon v7 appears pivotal in these diseases, as treat-
ment with anti-CD44v7 antibodies led to complete re-
mission in TNBS-induced colitis, in contrast to v6-specific
therapy (14). Furthermore, (a) CD44v7- and CD44v6/v7-
deficient mice were equally resistant to TNBS colitis; (b)
CD44v7-deficient bone marrow cells were able to fully
protect against TNBS colitis in adoptive transfer experi-
ments; and (c) both CD44v7- and CD44v6/v7-deficient
mice exhibited a similar degree of apoptotic cells in the
early inflamed lesions.
Immunomodulatory therapies, such as treatment with
anti–IL-12, anti-CD40, and recombinant IL-10, have been
applied successfully in experimental colitis (6, 28, 33). We
have observed a strong downregulation of IL-12 in
CD44v7- and CD44v6/v7-deficient mice when chal-
lenged with TNBS or when cross-bred with IL-10–defi-
cient mice. The Th1-polarizing cytokine IL-12 is known
to play a major role in both TNBS-induced colitis and
Crohn’s disease as well as sustaining the chronic phase in
Figure 5. Apoptosis is increased
in CD44v72/2 and CD44v6/v72/2
mice. (A) TUNEL assay of colonic
sections from TNBS-treated mice.
CD44 wild-type (wt), CD44v6/
v72/2, and CD44v72/2 mice were
treated with TNBS or not treated
(co), and frozen with sections
stained with hematoxylin and eosin
(HE). Apoptotic nuclei were de-
tected with biotinylated nucleotides
(DeadEnd; Promega) followed ei-
ther by diaminobenzidine (DAB)
detection or by fluorescein-dUTP
(Roche Molecular Biochemicals)
(FITC). (B) LPMCs from TNBS-
treated wild-type (WT), CD44v72/2, and CD44v6/v72/2 mice were incubated with annexin V–FITC (CLONTECH Laboratories, Inc.) and propid-
ium iodide (PI). The percentage of live cells is indicated for one of four experiments.2061 Wittig et al.
IL-10–deficient mice (33–36). Administration of anti-
CD40L antibodies prevents the priming of Th 1 cells due
to an inhibition of IL-12 secretion (28). As shown here,
CD40–CD40L ligation specifically induced CD44v7 ex-
pression on mouse LN cells. Similarly, CD44 variant iso-
forms were upregulated on human leukocytes upon CD40
stimulation (our unpublished data).
In this study, the strong reduction of the initial inflam-
matory response in the CD44v72/2 mice is correlated with
increased apoptotic activity in the lesions. CD44v7, which
is upregulated upon CD40 ligation, thus appears to protect
activated leukocytes from AICD. There is compelling evi-
dence that pan-CD44 promotes survival of activated lym-
phocytes, fibroblasts, and carcinoma cells (37–41). CD44
may thus have a major impact in promoting the persistence
of inflammation in autoimmune diseases and possibly in
preventing tumor cells from undergoing apoptosis. The in-
creased apoptotic activity of activated leukocytes results in a
rapid clearing of the inflammation by phagocytosis of the
dead cells. This process may lead to systemic tolerance due
to presentation of antigens from the dead cells by the
phagocytosing APCs and reduction of the inflammation by
production of IL-10 from the dying lymphoid cells (42).
Analyses of surface molecules from inflamed regions of
patients or mice with Th1-type autoimmune disease or
chronic inflammations, such as systemic lupus erythemato-
sus, rheumatoid arthritis, experimental autoimmune en-
cephalomyelitis, insulin-dependent diabetes mellitus, and
delayed-type hypersensitivity reactions all correlate with
high expression levels of CD44 (43–47). Using CD44 re-
agents specific for the variant isoforms, disease scores in
experimental autoimmune encephalomyelitis could be
strongly reduced (48). By specifically deleting exons v6 and
v7 in mice, without affecting the expression of the other
exons, we could now unequivocally demonstrate that the
region encoded by exon v7 rather than the standard region
of CD44, whose expression is unaffected by the mutation,
is causally involved in chronic bowel inflammation.
In contrast to the CD44 standard isoform, devoid of any
variant regions, which is expressed ubiquitously, we now
demonstrate that CD44v7 expression is restricted to lym-
phocytes of inflammatory lesions in Th1-polarized experi-
mental colitis. The same finding was observed in Th1- but
not Th2-polarized CD41 splenic T cells (Johansson, B.,
and U. Günthert, manuscript in preparation). In addition,
in an earlier study we have shown that stimulation with
IFN-g in vitro results in an upregulation of CD44 variant
isoforms in human leukocytes (49). Thus, CD44v7 appears
to be a new marker for Th1-polarized activated T cells.
Our ongoing research in mouse models for rheumatoid
arthritis, experimental autoimmune encephalomyelitis, and
delayed-type hypersensitivity reactions indicates that the
CD44 variant region is also of major importance in mainte-
nance of the inflammatory reactions in these diseases. This
finding may well open a new strategy of therapeutic inter-
vention in autoimmune diseases by interfering with
CD44v7 as a potent inhibitor of apoptosis. Therapeutic in-
tervention strategies promoting cell death by interfering
with inhibitors of apoptosis have been suggested in the
treatment of patients with autoimmune disease and tumors
(50).
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